The DOI matches its Crossref record.
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia
Abstract
Key Points: In newly diagnosed ITP, addition of rituximab to dexamethasone yields higher sustained response rates than dexamethasone alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
American Society of Hematology 2019 guidelines for immune thrombocytopenia
Neunert, C., Terrell, D. R., Arnold, D. M., Buchanan, G., Cines, D. B., Cooper, N., Cuker, A., Despotovic, J. M., George, J. N., Grace, R. F., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000966 · Cited by 1,406
Clinical updates in adult immune thrombocytopenia
Lambert, M. P., & Gernsheimer, T. B. (2017) · Blood · doi:10.1182/blood-2017-03-754119 · Cited by 445
International Recommendations on the Diagnosis and Treatment of Acquired Hemophilia A
Tiede, A., Collins, P., Knoebl, P., Teitel, J., Kessler, C., Shima, M., Di Minno, G., d’Oiron, R., Salaj, P., Jiménez-Yuste, V., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.230771 · Cited by 401
“This regimen has also been used in immune thrombocytopenia.(67,68) Although not licensed for the treatment of AHA, we suggest adding rituximab to first-line IST in patients with poor prognostic markers, in those with contraindications against corticosteroids, or as second-line therapy.”
MethodSystematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Metadata
- Authors
- Gudbrandsdottir, S., Birgens, H. S., Frederiksen, H., Jensen, B. A., Jensen, M. K., Kjeldsen, L., Klausen, T. W., Larsen, H., Mourits-Andersen, H. T., Nielsen, C. H., Nielsen, O. J., Plesner, T., Pulczynski, S., Rasmussen, I. H., Rønnov-Jessen, D., & Hasselbalch, H. C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-03-14
- Volume
- 121
- Issue
- 11
- Pages
- 1976-1981
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2042239736
- Cited by
- 176
- References
- 0
- FWCI
- 9.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. https://app.cochat.ai/papers/10.1182/blood-2012-09-455691
- The paper
- Gudbrandsdottir, S., Birgens, H. S., Frederiksen, H., Jensen, B. A., Jensen, M. K., Kjeldsen, L., Klausen, T. W., Larsen, H., Mourits-Andersen, H. T., Nielsen, C. H., Nielsen, O. J., Plesner, T., Pulczynski, S., Rasmussen, I. H., Rønnov-Jessen, D., & Hasselbalch, H. C. (2013). Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. https://doi.org/10.1182/blood-2012-09-455691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.